Previous studies have shown a significant positive correlation between performance in cognitive tests and 11C-UCB-J binding in the hippocampus [35], which suggested that SV2A by PET could be a promising biomarker of synaptic density for tracking AD progression [15, 36, 37]. Here, SV2A is linked to Alzheimer disease.